Beximco Pharmaceuticals Limited (BXP.L) Comparison with companies in other sectors?

Beximco Pharmaceuticals Limited has a share price of 446.11M. You can analyze Beximco Pharmaceuticals Limited (BXP.L) competitors across different market sectors through stock heatmaps.

What are BXP.L's NET and operating margins?

Beximco Pharmaceuticals Limited (BXP.L) operating margin is around 0.20, and net profit margin is approximately 0.14 as of the latest reports.

In what way does BXP.L's earnings per share (EPS) trend reflect its financial momentum?

Beximco Pharmaceuticals Limited (BXP.L) EPS is 0.09 (If EPS value is positive, then “signals consistent profit growth” if Negative then “signals consistent loss”). This metric is also critical in assessing valuation metrics like the P/E ratio for Beximco Pharmaceuticals Limited is 4.33, and the company’s ability to reinvest or distribute profits.

What does a high ROE mean for Beximco Pharmaceuticals Limited?

A high ROE suggests efficient use of shareholder equity to generate profit. It often signals strong management and profitability.

How do I know if AAPL is overvalued or undervalued?

Check valuation ratios for Beximco Pharmaceuticals Limited like P/E which is 4.43, P/B which is 0.57, and PEG which is 0.41. Compare them with sector averages to evaluate if the stock is priced fairly.

Beximco Pharmaceuticals Limited

BXP.L•LSE

Healthcare

Drug Manufacturers - Specialty & Generic

£39.00

£0.00(0.00%)

Beximco Pharmaceuticals Limited (BXP.L) Fundamental Analysis: Financial Health, Valuation, and Key Ratios

Dive into Apple Inc.’s fundamentals including valuation ratios, profitability, efficiency metrics, and financial health. Use this data to assess long-term investment quality and compare it with sector benchmarks.

EPS (TTM)

$0.09

P/E Ratio

4.33

ROE

0.13%

Net Margin

0.14%

Key Financial Metrices

Valuation Metrics

4 metrics

Market CapTotal market value of outstanding shares

$173.98M

Shares OutstandingTotal number of shares issued

$446.11M

Book Value/ShareNet worth per share

$120.21

Revenue/ShareAnnual revenue per share

$103.88

Profitability Metrics

6 metrics

EPS (TTM)Earnings per share trailing twelve months

$0.09

Net MarginNet income as percentage of revenue

13.71%

Operating MarginOperating income as percentage of revenue

19.90%

ROEReturn on shareholders' equity

13.12%

ROAReturn on total assets

8.61%

ROCEReturn on capital employed

14.81%

Cash Flow Metrics

3 metrics

Free Cash Flow/ShareCash generated per share after capex

$8.75

Cash/ShareCash and equivalents per share

$5.28

FCF YieldFree cash flow as percentage of market cap

13.83%

Dividend Metrics

2 metrics

Dividend/ShareAnnual dividend payment per share

$5.43

Dividend YieldAnnual dividend as percentage of stock price

8.59%

Financial Ratios Analysis data is not available for BXP.LFinancial Ratios Analysis details for BXP.L are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Sector Benchmarking data is not available for BXP.LSector Benchmarking details for BXP.L are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Understanding Fundamental Analysis for Beximco Pharmaceuticals Limited Investment Decisions

What is Fundamental Analysis?

Fundamental analysis is a method used to assess the intrinsic value of Beximco Pharmaceuticals Limited. Using financial reports, management structure, competitive position, and market environment, investors can determine whether the stock is undervalued or overvalued. This analysis helps investors like you make more informed investment decisions, taking into account Beximco Pharmaceuticals Limited's unique business strengths and challenges.

Key Financial Metrics for Beximco Pharmaceuticals Limited

For Beximco Pharmaceuticals Limited, essential financial indicators include EPS 0.09, PE 4.33, and ROE 0.13. These key ratios reveal insights into Beximco Pharmaceuticals Limited's profitability, valuation, and operational health. Understanding these metrics enables you to compare Beximco Pharmaceuticals Limited with its industry peers and decide whether it presents a viable investment opportunity.

Profitability and Operational Efficiency of Beximco Pharmaceuticals Limited

Metrics like Net Margin 13.71% and ROA 8.61% shed light on how well Beximco Pharmaceuticals Limited is generating profits. A high profitability ratio often indicates strong management and a solid business model, which are essential for long-term growth. These metrics are crucial in assessing whether Beximco Pharmaceuticals Limited can sustain its operations and continue growing in the future.

Valuation and Market Position of Beximco Pharmaceuticals Limited

Using ratios such as P/B Ratio 0.57 and PEG Ratio 0.41, investors can assess whether Beximco Pharmaceuticals Limited is appropriately valued based on its financials and growth potential. These figures, combined with Beximco Pharmaceuticals Limited's market capitalization, give insight into its competitive positioning and investor expectations, helping you make informed decisions on pricing and value.

Financial Health and Risk Assessment for Beximco Pharmaceuticals Limited

Financial health indicators, such as Debt/Equity Ratio 0.12 and Cash Flow $8.75, provide a snapshot of Beximco Pharmaceuticals Limited's ability to meet financial obligations and handle economic setbacks. A company with a strong balance sheet and solid cash flow, like Beximco Pharmaceuticals Limited, is more likely to weather financial storms, making it a safer investment.

Long-Term Investment Strategy for Beximco Pharmaceuticals Limited

Investing in Beximco Pharmaceuticals Limited based on fundamental analysis emphasizes long-term business growth rather than short-term market trends. Investors looking at Beximco Pharmaceuticals Limited focus on its solid financial performance, industry standing, and competitive advantages, all of which suggest sustainable growth and the potential for steady returns over time.

Fundamental Analysis FAQ

;